The Veronesi Foundation's breast cancer campaign arrives in 23 Italian airports

Italian airports are also participating in the campaign "There are no excuses!" promoted by the Veronesi Foundation to raise awareness among women on the importance of cancer prevention and early diagnosis.

The initiative, carried out in collaboration with Assaeroporti, involves 23 Italian airports, which during the month of October make their information channels available to spread the message of the campaign and reach thousands of passengers every day.

October is traditionally the month dedicated to raising awareness of breast cancer, the most common neoplasm among the female population. In Italy, more than 53,600 new diagnoses are recorded every year, according to data from the AIRTUM-AIOM 2025 Report. Thanks to screening programs and advances in therapies, survival five years after breast cancer diagnosis has reached 88%. Early diagnosis therefore continues to play a central role, making it particularly important to undergo regular tests based on age and risk profile.

The message arrives in the terminals of Italian airports
With "There are no excuses!", Fondazione Veronesi invites us not to postpone checks and screenings. Bringing the campaign to airports makes it possible to intercept a wide and diversified audience during a moment of everyday life such as travel.

The Italian airports that have joined are Alghero, Ancona, Bergamo, Bologna, Cagliari, Catania, Comiso, Cuneo, Florence, Pisa, Forlì, Genoa, Milan Linate, Milan Malpensa, Naples, Salerno, Olbia, Palermo, Parma, Rimini, Turin, Trapani and Trieste.

The presence of the campaign in the terminals thus transforms airport spaces also into places of information and awareness, combining passenger services with a message dedicated to health.

Veronesi Foundation's research on breast cancer
The Veronesi Foundation has been supporting research projects on women's cancers for years, with the aim of developing more effective therapies and improving patients' quality of life. Since 2025, the Foundation has also launched a research platform dedicated to breast cancer, focused on advanced clinical trials for the personalization of care in patients with hormone-positive, ER-positive and HER2-negative operable breast cancer, the most common subtype and accounting for about 70% of cases.